Ju‐Whei Lee

689 total citations
26 papers, 165 citations indexed

About

Ju‐Whei Lee is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Ju‐Whei Lee has authored 26 papers receiving a total of 165 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Hematology. Recurrent topics in Ju‐Whei Lee's work include Acute Myeloid Leukemia Research (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Ju‐Whei Lee is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Ju‐Whei Lee collaborates with scholars based in United States, Israel and Australia. Ju‐Whei Lee's co-authors include Lynne I. Wagner, Nathaniel S. O’Connell, Edward H. Ip, Ilana F. Gareen, Ruth C. Carlos, Fengmin Zhao, Robert J. Gray, David Cella, Mark R. Litzow and John Devin Peipert and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ju‐Whei Lee

24 papers receiving 163 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ju‐Whei Lee United States	8	56	48	33	29	28	26	165
Morgani Rodrigues Brazil	9	44 0.8×	123 2.6×	26 0.8×	19 0.7×	51 1.8×	32	225
Marie-Émilie Dourthe France	6	45 0.8×	26 0.5×	40 1.2×	15 0.5×	35 1.3×	27	135
Rajni Agarwal‐Hashmi United States	5	54 1.0×	76 1.6×	16 0.5×	15 0.5×	44 1.6×	11	155
Nick Stuart United Kingdom	5	76 1.4×	11 0.2×	11 0.3×	20 0.7×	20 0.7×	7	133
J.-Y. Génot France	5	172 3.1×	29 0.6×	12 0.4×	37 1.3×	15 0.5×	9	253
Stefana Impera Italy	6	50 0.9×	85 1.8×	20 0.6×	13 0.4×	35 1.3×	14	140
Megan Dunne United States	8	200 3.6×	22 0.5×	65 2.0×	110 3.8×	34 1.2×	18	318
Fuminori Iwasaki Japan	8	53 0.9×	30 0.6×	48 1.5×	17 0.6×	33 1.2×	25	189
Christina Große-Thie Germany	10	149 2.7×	10 0.2×	53 1.6×	60 2.1×	38 1.4×	23	251
Nupur Mittal United States	9	31 0.6×	39 0.8×	34 1.0×	19 0.7×	45 1.6×	37	217

Countries citing papers authored by Ju‐Whei Lee

Since Specialization

Citations

This map shows the geographic impact of Ju‐Whei Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ju‐Whei Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ju‐Whei Lee more than expected).

Fields of papers citing papers by Ju‐Whei Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ju‐Whei Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ju‐Whei Lee. The network helps show where Ju‐Whei Lee may publish in the future.

Co-authorship network of co-authors of Ju‐Whei Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Ju‐Whei Lee. A scholar is included among the top collaborators of Ju‐Whei Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ju‐Whei Lee. Ju‐Whei Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peipert, John Devin, Fengmin Zhao, Ju‐Whei Lee, et al.. (2025). Overall side‐effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments. Cancer. 131(S2). e70084–e70084.

Palmisiano, Neil, Ju‐Whei Lee, David F. Claxton, et al.. (2024). A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol. SHILAP Revista de lepidopterología. 5(5). 951–956. 1 indexed citations

Lee, Ju‐Whei, Ilana F. Gareen, Shaji Kumar, et al.. (2024). Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials. Journal of Pain and Symptom Management. 69(4). 370–384.

Peipert, John Devin, Fengmin Zhao, Ju‐Whei Lee, et al.. (2024). Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma. JAMA Network Open. 7(3). e243854–e243854. 10 indexed citations

O’Connell, Nathaniel S., Fengmin Zhao, Ju‐Whei Lee, et al.. (2023). Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. Journal of Clinical Oncology. 42(3). 266–272. 23 indexed citations

Obeng‐Gyasi, Samilia, Noah Graham, Shaji Kumar, et al.. (2022). Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. Blood Cancer Journal. 12(4). 53–53. 16 indexed citations

Rajdev, Lakshmi, Ju‐Whei Lee, Steven K. Libutti, et al.. (2022). A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. Investigational New Drugs. 40(6). 1306–1314. 7 indexed citations

Lee, Ju‐Whei, Howard A. Zaren, Rachel E. Lerner, et al.. (2022). Cluster-randomized trial to evaluate the implementation of reproductive health care in cancer care delivery in community oncology practices: Results from ECOG-ACRIN E1Q11.. Journal of Clinical Oncology. 40(16_suppl). 1519–1519. 1 indexed citations

Ip, Edward H., Santiago Saldana, Kathy D. Miller, et al.. (2021). Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events. Cancer. 127(24). 4546–4556. 3 indexed citations

10.

Ganzel, Chezi, Ju‐Whei Lee, Hugo F. Fernández, et al.. (2021). CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. Blood Advances. 5(22). 4560–4568. 20 indexed citations

11.

Palmisiano, Neil, Ju‐Whei Lee, David F. Claxton, et al.. (2021). Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152. Blood. 138(Supplement 1). 3407–3407. 7 indexed citations

12.

Chen, Alice P., Keith T. Flaherty, Peter J. O’Dwyer, et al.. (2020). Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial. JCO Precision Oncology. 4(4). 1207–1216. 8 indexed citations

13.

Peipert, John Devin, Fengmin Zhao, Ju‐Whei Lee, et al.. (2020). Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients.. Journal of Clinical Oncology. 38(15_suppl). e19136–e19136. 4 indexed citations

14.

Shi, Qiuling, Ju‐Whei Lee, Xin Shelley Wang, et al.. (2020). Testing Symptom Severity Thresholds and Potential Alerts for Clinical Intervention in Patients With Cancer Undergoing Chemotherapy. JCO Oncology Practice. 16(9). e893–e901. 2 indexed citations

15.

Zhao, Fengmin, John Devin Peipert, Ju‐Whei Lee, et al.. (2020). Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.. Journal of Clinical Oncology. 38(15_suppl). e19132–e19132. 3 indexed citations

16.

Mantha, Simon, Debra A. Goldman, Sean M. Devlin, et al.. (2014). Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era. Blood. 124(21). 948–948. 3 indexed citations

17.

Luskin, Marlise R., Ju‐Whei Lee, Hugo F. Fernández, et al.. (2014). Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML. Blood. 124(21). 2599–2599. 7 indexed citations

18.

Ganzel, Chezi, Judith Manola, Dan Douer, et al.. (2013). Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008. Blood. 122(21). 63–63. 1 indexed citations

19.

Marur, Shanthi, Ju‐Whei Lee, Anthony J. Cmelak, et al.. (2012). ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).. Journal of Clinical Oncology. 30(15_suppl). 5566–5566. 21 indexed citations

20.

Yates, J. Frank, Ju‐Whei Lee, & Hiromi Shinotsuka. (1992). Cross-National Variation in Probability Judgment. PsycEXTRA Dataset. 30(6). 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact